Ardelyx, Inc.
Viés de alta

ARDX Strong upgrade from a top financial firm

Atualizado
ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.

On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00
This would be a 581% gain from the current level.

Looking forward to read your opinion about it.
Trade fechado: objetivo atingido
Target reached! 6X gain!
ardelyxARDXbuyFundamental AnalysisTechnical IndicatorssignalstockpicksStocksstocksignalsstockstobuystocktradingTrend Analysis

Também em:

Aviso legal